Xplico is pleased to announce that Peter Abelin has joined our valuation team.
Peter has more than 25 years’ experience from the life science industry working with equity portfolio management, financial research and pharmaceutical development at Swedbank Robur, AMF Pension, SEB Enskilda, Astra AB and as an MD. Peter brings a lot of expertise in assessing equity investments and life science equity valuation and will work closely with our clients valuating their business. Peter has combined his MD with BSc Econ and CE Financial Analyst.

(June 2016)